HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics reported Q1 2026 total revenue of $376.7 million, a 42% increase from $264.9 million in Q1 2025, driven by strong royalty revenue growth and increased product sales. The company announced a new $1 billion share repurchase program, with an expectation to buy back at least $400 million in 2026, reflecting confidence in its business and strong cash generation. Halozyme reaffirmed its 2026 financial guidance, projecting total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, and non-GAAP diluted earnings per share of $7.75 to $8.25.
Key figures
- Eps
- 1.22
- Eps Beat
- 0
- Revenue
- 376708000
- Guidance
- Total Revenue $1.710 - $1.810 billion, Royalty Revenue $1.130 - $1.170 billion, Adjusted EBITDA $1.125 - $1.205 billion, Non-GAAP Diluted EPS $7.75 - $8.25
- Revenue Yoy
- 42%
- Ebitda
- 218250000
- Net income
- 150049000
- Total assets
- 2672719000
- Cost of sales
- 79238000
- Product sales
- 130424000
- Adjusted ebitda
- 229499000
- Royalty revenue
- 240681000
- Operating income
- 184517000
- Total liabilities
- 2453083000
- Marketable securities
- 8873000
- Cash and cash equivalents
- 309749000
- Total stockholders equity
- 219636000
- Amortization of intangibles
- 29512000
- Gaap diluted earnings per share
- 1.22
- Research and development expense
- 25560000
- Non gaap diluted earnings per share
- 1.6
- Selling general and administrative expense
- 57881000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.